8 research outputs found
The association between coronary flow rate and impaired heart rate recovery in patients with metabolic syndrome: A preliminary report
Background: The aim of this study is to evaluate heart rate recovery (HRR) and association between coronary flow rate and HRR in patients with metabolic syndrome (MS) who had morphologically normal coronary angiogram.Methods: Study population included 43 patients with MS and 37 control subjects without MS. All patients were selected from individuals who had recently undergone coronary angiography in our hospital and were diagnosed as having angiographically normal coronary arteries. Exercise stress test results obtained prior to coronary angiography were evaluated for calculating HRR and other parameters. In addition, coronary flow was objectively evaluated for each major coronary artery in each subject using TIMI frame count method.Results: All HRR values calculated were detected significantly lower in MS group compared to controls (HRR first: 32 ± 9 vs. 37 ± 10; p = 0.01, second: 46 ± 11 vs. 52 ± 11; p = 0.03, third: 51 ± 12 vs. 59 ± 12; p = 0.00, fourth: 54 ± 13 vs. 61 ± 2; p = 0.02). TIMI frame counts for each major epicardial coronary artery and mean TIMI frame count were also found to be significantly higher in MS group compared to controls (left anterior descending artery:51 ± 24 vs. 39 ± 15; p = 0.009, left circumflex artery: 32 ± 11 vs. 24 ± 7; p = 0.001, right coronary artery: 33 ± 14 vs. 24 ± 10; p = 0.003, mean TIMI frame count: 38 ± 15 vs. 29 ± 9;p = 0.002). Additionally, significant negative correlations were also detected between HRR first minute and coronary TIMI frame count values in patients with MS. None of MS parameters did not affect HRR values, however mean TIMI frame count independently associated with HRR first minute (p = 0.04) in patients with MS.Conclusions: Impaired coronary blood flow occurring in MS might be a clue of autonomic dysfunction in addition to previously known endothelial dysfunction.
Effect of Infliximab Treatment on QT Intervals in Patients With Ankylosing Spondylitis
Background: Cardiovascular complications are one of the most common and the most serious extraskeletal manifestations of ankylosing spondylitis (AS). Infliximab, a monoclonal antibody against tumor necrosis factor, is widely used in the treatment of AS. QT dispersion (QTd), which relates to left ventricular function and is used as an index of cardiac dysrhythmia, may be useful as a prognostic guide. Early detection of possible cardiac involvement may not be clinically evident, whereas it may be detected by electrocardiography
The Safety and Efficacy of Etanercept on Cardiac Functions and Lipid Profile in Patients With Active Rheumatoid Arthritis
Objectives: Patients with rheumatoid arthritis (RA) are known to be at increased cardiovascular risk. Etanercept is a tumor necrosis factor alpha (TNF-alpha) blocking agent that has been successfully used in the treatment of RA. We sought to assess the effects of etanercept on cardiac functions and lipid profile in RA patients without overt cardiac disease
Correction to: Impaired coronary blood flow may be related to elevated homocysteine levels in patients with metabolic syndrome
Retrospective evaluation of patients diagnosed solid pseudopapillary neoplasms of the pancreas
Purpose: Solid pseudopapillary neoplasm (SPN) is a rare, low-grade
neoplasm with excellent prognosis. In this study, we evaluated
clinicopathological characteristics of patients diagnosed with SPN
retrospectively.
Methods: This is a retrospective study intended to characterize patients
with the diagnosis of SPN between 2005 and 2015. Clinicopathological
features, recurrence rate, and overall survival of 28 patients were
recorded. Malignant SPN criteria were defined as the presence of distant
metastasis (developed at diagnosis or during follow up) or lymph node
involvement.
Results: The mean age at diagnosis was 42 (range: 17-41). Among
patients, 82\% (n = 23) were female and 17.9\% (n = 5) were male. The
mean size of tumor was 5.81 cm (range: 2-15). The mean follow up period
was 55.6 months, 1-year survival was 96.5\% and 5-year survival rate was
88\%. A total of 25 patients were alive at the end of follow-up period
and 3 of the patients became exitus due to disease. Two patients had a
metastatic presentation in livers at the diagnosis and metastasis
developed in 3 patients during follow-up (liver of 1 patient, peritoneum
in 1 patient and liver and peritoneum in 1 patient). The reason of
admission was headache in 68\% patients. The type of operation was
frequently subtotal pancreatectomy (n = 11, 39.3\%) and distal
pancreatectomy (n = 10, 35.7\%). Tumors were located frequently in body
and tail regions (n = 18, 64.3\%) and the number of patients with
malignant criteria was 6 (21.4\%). Although the mean age of malignant
patients was significantly higher than benign patients (P = 0.046),
there was no significant difference between 2 groups in terms of gender,
tumor size, capsule invasion, perineural invasion, vascular invasion,
and margin status.
Conclusion: SPN is a rarely seen tumor with low malignity potential.
Surgical resection provides long-term survival rate even in local
invasion or metastasis conditions. (C) 2018 Elsevier Inc. All rights
reserved